Top of this page
Skip navigation, go straight to the content

Partnering with patients is key to innovation

  • Posted by

    At UCB, we want to develop innovative medicines that are valued by patients. That is why we work with people who have epilepsy to learn how we can meet their needs.

    After all, we can develop the most innovative medicines in the world but if they do not reach patients, no good comes from that.



    This recently-aired segment on ‘The Balancing Act’ – a morning show broadcast on the Lifetime network in the US – highlights some of the challenges faced by people with epilepsy, as well as the role of UCB in finding solutions.

    As Susan Axelrod, founder of Citizens United for Research in Epilepsy (CURE), explains, 30% of epilepsy patients are not responding to current treatments. More options are clearly needed.

    Greater awareness and earlier diagnosis can also help to improve care for people with epilepsy. Susan’s own daughter had her first seizure at just seven months of age but waited 18 years for diagnosis. Now, aged 34, she has been seizure-free for 15 years. These are the kinds of success stories we want to be part of.

    The show also features the testimonials of two patients who share the stories of how they are dealing with their condition. In both cases, after a difficult start, these patients now have their epilepsy under control and are living full and active lives.

    At UCB, we listen to patient experiences and this informs our research and development, as well as the patient initiatives we support. From establishing an online epilepsy community to working with seizure response dogs, we are committed to playing our part in the epilepsy community.

    We are Inspired by Patients. Driven by Science. By embracing patient-inspired science, we are also connecting with academics, health professionals, governments and others to ensure that we all play our part in delivering better quality of life for people with epilepsy.

    Tags:
    Categories:
    Share:

Leave a Comment